{
  "meta": {
    "timestamp": "2025-01-06T11:14:45.763851",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "GH Research PLC",
      "symbol": "GHRS",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory Challenges: GH001 is based on 5-MeO-DMT, a Schedule I controlled substance in the U.S., posing significant regulatory hurdles.",
            "Clinical Trial Risks: Success depends on outcomes of ongoing and future clinical trials for GH001 in treating TRD and other mental health disorders.",
            "Market Competition: High competition in the mental health therapeutics market risks GH Research being outpaced by competitors.",
            "Public Perception and Ethical Concerns: Controversy around the use of psychedelics in medicine could hinder adoption and market penetration."
          ],
          "controversies": [
            "Use of psychedelics in medicine remains controversial, potentially affecting public and investor perception.",
            "Regulatory classification of 5-MeO-DMT as a Schedule I substance in the U.S. complicates approval and commercialization."
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical concerns regarding the use of psychedelics in mental health treatment."
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "GH Research Goes Public To Turn 5-MeO-DMT Into Medicine For ... - Forbes",
              "snippet": "A prospectus filed by GH Research to the Securities and Exchange Commission (SEC) on June 21 notes that 5-MeO-DMT is currently classified as a Schedule I drug in the U.S. and any product ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174790+00:00",
              "published_date": null,
              "source_hash": "c21cc8365237721d3534717eeedf64c2"
            },
            {
              "url": "",
              "title": "GH Research Announces Grant of European Patent Covering all Mebufotenin ...",
              "snippet": "The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cover all mebufotenin (5-MeO-DMT) and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174839+00:00",
              "published_date": null,
              "source_hash": "dc6b9053ef0a8c813995d9940ed53566"
            },
            {
              "url": "",
              "title": "GH Research",
              "snippet": "GH Research is a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. With its novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) products and current clinical development programs in treatment-resistant depression (TRD), bipolar II disorder with a depressive episode (BDII) and postpartum ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338252+00:00",
              "published_date": null,
              "source_hash": "250f8144272cba559de0eb33e9116e0a"
            },
            {
              "url": "",
              "title": "GH Research Announces Grant of European Patent Covering all Mebufotenin ...",
              "snippet": "DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to trans...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174862+00:00",
              "published_date": null,
              "source_hash": "5a81fc41f810249e5dc1363e4d5401b2"
            },
            {
              "url": "",
              "title": "GH Research Files to Go Public Only Two Months After Raising $125 ...",
              "snippet": "GH Research is also planning clinical trials for what it is calling GH002, a 5-MeO-DMT product formulated for administration via injection. The company believes that GH002 will find use for patients with \"underlying airway or pulmonary disease or in situations where it is difficult to assure that the GH001 inhalation is performed adequately, such as in acute psychiatric emergency care ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174871+00:00",
              "published_date": null,
              "source_hash": "8abb7a81a29f2076c65c91d61000c07c"
            },
            {
              "url": "",
              "title": "GH Research Receives European Patent for Groundbreaking Treatment of ...",
              "snippet": "GH Research Receives European Patent for Mebufotenin (5-MeO-DMT) and Salt Products in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionDUBLIN, Ireland, Jan. 18, 2024 - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of psychiatric and neurological disorders, announced today that it has been granted ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174881+00:00",
              "published_date": null,
              "source_hash": "8f2db364dcc0d68e0443008cd3795ea3"
            },
            {
              "url": "",
              "title": "GH Research Announces Grant of European Patent Covering all - GlobeNewswire",
              "snippet": "GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174891+00:00",
              "published_date": null,
              "source_hash": "71854721b3c413af232240fa622664b3"
            },
            {
              "url": "",
              "title": "GH Research Announces Grant of European Patent Covering all Mebufotenin ...",
              "snippet": "GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). GH Research PLC's annual report on Form 20-F/A filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2022, is available at www ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174900+00:00",
              "published_date": null,
              "source_hash": "1b4eaa171685afee10a2bc0cf738abcf"
            },
            {
              "url": "",
              "title": "GH Research: Updates on Clinical Development Programs",
              "snippet": "5-MEO-DMT developer GH Research has provided an update on its main clinical programs. The company is notoriously short on communications outside of the obligatory company updates, so investors are always keen on getting a glimpse of GH Research's latest announcements. ... Sept. 29, 2023 (GLOBE NEWSWIRE) \u2014 GH Research PLC (Nasdaq: GHRS), a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174909+00:00",
              "published_date": null,
              "source_hash": "ce9e9ba6eae94931d284a110acc16ead"
            },
            {
              "url": "",
              "title": "GH Research Provides Updates and Guidance on its Clinical ... - BioSpace",
              "snippet": "About GH Research PLC. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:15.174922+00:00",
              "published_date": null,
              "source_hash": "53e97e14814916ad13490b8271837ef4"
            },
            {
              "url": "",
              "title": "GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates",
              "snippet": "GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the ... studies and clinical trials, regulatory submissions and approvals and ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:18.732662+00:00",
              "published_date": "2024-11-14T04:00:00+00:00",
              "source_hash": "0c658c91ad3323cb3e0b89d41f7b9de0"
            },
            {
              "url": "",
              "title": "GH Research Plc",
              "snippet": "GH Research Plc operates as a holding company ... The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:18.732746+00:00",
              "published_date": "2023-12-31T13:19:00+00:00",
              "source_hash": "43256b8b05b6c2694321e72ed475a547"
            },
            {
              "url": "",
              "title": "GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates",
              "snippet": "GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of ... currently planned preclinical studies and clinical trials, regulatory submissions and approvals and their effects on ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC regulatory challenges 5-MeO-DMT",
              "retrieved_at": "2025-01-06T18:14:18.732762+00:00",
              "published_date": "2024-11-14T00:00:00+00:00",
              "source_hash": "e7a9f68a93ba6829b58ece11a4034363"
            },
            {
              "url": "",
              "title": "GH Research Goes Public To Turn 5-MeO-DMT Into Medicine For Treatment ...",
              "snippet": "That's what Ireland-based GH Research PLC is after with their formulation of 5-MeO-DMT, dubbed \"GH001\": Tackling the crippling symptoms of chronic depression. Specifically, the group is ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338364+00:00",
              "published_date": null,
              "source_hash": "4eedf0be3966e2e7fbd8876af76af9b0"
            },
            {
              "url": "",
              "title": "GH Research PLC (GHRS): history, ownership, mission, how it works ...",
              "snippet": "[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of GH Research PLC (GHRS) Company Overview GH Research PLC, listed under the ticker GHRS, is a biopharmaceutical company focused on developing psychedelic-based therapies, particularly for mental health disorders. Founded in 2020 and based in Dublin, Ireland, the company aims to innovate within the field of ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338383+00:00",
              "published_date": null,
              "source_hash": "f5ad35dbfbe95c2d24a21b35e8c95d28"
            },
            {
              "url": "",
              "title": "GH Research pushes forward with DMT trials, drug approvals",
              "snippet": "Irish psychedelic biotech firm GH Research PLC (Nasdaq: GHRS), which is still in the pre-revenue stage as of New Year's Eve, posted a $35.6 million loss for 2023 amid multiple ongoing psychedelic drug studies for potential new products that the company says are promising. GH Research had $222.7 million in cash left at the end of the year, and spent just $29.8 million on research and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338399+00:00",
              "published_date": null,
              "source_hash": "787b117260f2e8f54794a15209eefddc"
            },
            {
              "url": "",
              "title": "About Us | GH Research",
              "snippet": "GH Research was founded in 2018, and since then, two of our novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates have entered clinical development; our lead product candidate, GH001, is currently being investigated in a randomized, double-blind, placebo-controlled Phase 2b trial in patients with TRD, and in two open-label Phase 2a proof-of-concept ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338415+00:00",
              "published_date": null,
              "source_hash": "96daa555a94422cc9799cfe8db4f5708"
            },
            {
              "url": "",
              "title": "Pipeline | GH Research",
              "snippet": "With GH001, we have completed two Phase 1 clinical trials (GH001-HV-101 and GH001-HV-103) in healthy volunteers and a Phase 1/2 clinical trial (GH001-TRD-102) in patients with treatment-resistant depression (TRD).",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338427+00:00",
              "published_date": null,
              "source_hash": "204693ce6473a9b0b8decf80b0f7ea98"
            },
            {
              "url": "",
              "title": "GH Research Files to Go Public Only Two Months After Raising $125 ...",
              "snippet": "GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD).",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338440+00:00",
              "published_date": null,
              "source_hash": "596dc71f72889f6edfd0fe87c2392d0f"
            },
            {
              "url": "",
              "title": "Psychedelic Medicine: 5-MeO-DMT Formula For Treatment-Resistant ...",
              "snippet": "Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338452+00:00",
              "published_date": null,
              "source_hash": "463919bd231e8264fad287785821e21d"
            },
            {
              "url": "",
              "title": "GH Research Raises $125 Million to Fund DMT Treatment for Depression",
              "snippet": "GH Research Ireland closed a $125 million Series B financing round to fund the advancement of GH001, an inhaled version of 5-Methyoxy-N, N-dimethyltryptamine, or 5-MeO-DMT, the psychedelic ingredient found in the venom of certain toads and some plants or made synthetically.The financing is co-led by RA Capital and RTW Investments, LP, U.S.-based biopharmaceutical investment firms, alongside ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338464+00:00",
              "published_date": null,
              "source_hash": "6e6c807df01020d4fa937ef8f4e8e0fc"
            },
            {
              "url": "",
              "title": "GH Research Provides Business Updates and Highlights Key Upcoming ...",
              "snippet": "GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:20.338477+00:00",
              "published_date": null,
              "source_hash": "e484ee8421ce9eee06ec07259d11c336"
            },
            {
              "url": "",
              "title": "Top biotech VCs are betting on GH Research, a $1 billion psychedelics company that you've never heard of",
              "snippet": "GH Research declined to make executives available for this article. Over the past year, psychedelics companies have rushed to go public ... is developing a psychedelic treatment for TRD that ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:23.689782+00:00",
              "published_date": "2021-09-01T12:00:00+00:00",
              "source_hash": "03702a654a210d376a62ef389943c42e"
            },
            {
              "url": "",
              "title": "GH Research (NASDAQ:GHRS) Stock Quotes, Forecast and News Summary",
              "snippet": "Advances Psychedelic Drug Trials Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:23.689902+00:00",
              "published_date": "2024-09-10T18:25:00+00:00",
              "source_hash": "b266758e041014f96732ee18920efb64"
            },
            {
              "url": "",
              "title": "GH Research Plc",
              "snippet": "GH Research Plc operates as a holding company ... and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Sch\u00f6nharting ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:23.689935+00:00",
              "published_date": "2023-12-31T13:19:00+00:00",
              "source_hash": "50f7a3fa589ede3c12c05f62f54e77e6"
            },
            {
              "url": "",
              "title": "GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates",
              "snippet": "GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "GH Research PLC GH Research PLC public perception psychedelic therapies",
              "retrieved_at": "2025-01-06T18:14:23.689962+00:00",
              "published_date": "2024-09-30T00:00:00+00:00",
              "source_hash": "4c0168d8ee9d72fbd4c7b8088e4272de"
            },
            {
              "url": "",
              "title": "GHRS: GH Research - Full Company Report - Zacks.com",
              "snippet": "GH Research (GHRS) (Delayed Data from NSDQ) $7.74 USD. 7.74. 69,898 +0.01 (0.13%) Updated Dec 13, 2024 04:00 PM ET. ... GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278586+00:00",
              "published_date": null,
              "source_hash": "89587da856e5d06c2636e22e3e058812"
            },
            {
              "url": "",
              "title": "Breaking Down GH Research PLC (GHRS) Financial Health: Key Insights for ...",
              "snippet": "Key Risks Facing GH Research PLC (GHRS)Risk Factors Understanding the risk factors associated with GH Research PLC (GHRS) is essential for investors looking to navigate the complexities of the biotech and pharmaceutical landscape. The following insights outline internal and external risks that could impact the company's financial health.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278695+00:00",
              "published_date": null,
              "source_hash": "f07eec64935b28fa8794ff586674f2b0"
            },
            {
              "url": "",
              "title": "GH Research Reports Full Year 2023 Financial Results and - GlobeNewswire",
              "snippet": "GH RESEARCH PLC Consolidated Balance Sheet (Unaudited) (in thousands) At December 31, 2023: 2022 $'000 $'000: ASSETS Current assets Cash and cash equivalents: 78,420: 165,955: Other financial ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278775+00:00",
              "published_date": null,
              "source_hash": "1004f678fbfa8e37996e48a777f8bfbb"
            },
            {
              "url": "",
              "title": "GH Research Reports Second Quarter 2024 Financial Results and Provides ...",
              "snippet": "About GH Research PLC. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278787+00:00",
              "published_date": null,
              "source_hash": "f7930441292ab55c25941e301ddc75d3"
            },
            {
              "url": "",
              "title": "GH Research Q3 2024 Results and Clinical Updates - TipRanks",
              "snippet": "GH Research PLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders, with an emphasis on treatment-resistant depression. In its latest earnings report, GH Research shared financial results for the third quarter of 2024 and provided updates on key clinical trials.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278798+00:00",
              "published_date": null,
              "source_hash": "fe63e5e065dc9f01f1383985bbafc93e"
            },
            {
              "url": "",
              "title": "GH Research Reports First Quarter 2024 Financial Results - GlobeNewswire",
              "snippet": "GH Research PLC's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2023 is available at www.ghres.com and shareholders may receive ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278809+00:00",
              "published_date": null,
              "source_hash": "71b910b47594348701f031caf6da9a05"
            },
            {
              "url": "",
              "title": "GH Research's losses persist as it tries to lift FDA hold for GH001",
              "snippet": "Clinical-stage GH Research PLC (Nasdaq: GHRS) reported a wider second-quarter loss Tuesday as it pushes forward with its experimental depression treatment trials. The Dublin-based company lost $10.4 million in the quarter ending June 30. That compares with a loss of $7.7 million a year earlier. The higher net loss was largely due to higher ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278819+00:00",
              "published_date": null,
              "source_hash": "2298ca42436f52f59e5849b96c20c3b9"
            },
            {
              "url": "",
              "title": "GH Research Reports Second Quarter 2024 Financial Results and Provides ...",
              "snippet": "GH Research PLC. Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278830+00:00",
              "published_date": null,
              "source_hash": "e1332527f846834e12984b2d4d451d4f"
            },
            {
              "url": "",
              "title": "GH Research Reports Full Year 2023 Financial Results and Provides ...",
              "snippet": "GH Research PLC. Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278839+00:00",
              "published_date": null,
              "source_hash": "352a722d3dedf43850f64944e984d0f0"
            },
            {
              "url": "",
              "title": "GH Research PLC, GHRS:NMQ summary - FT.com - Financial Times",
              "snippet": "With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "GH Research PLC GH Research PLC clinical trial risks delays",
              "retrieved_at": "2025-01-06T18:14:26.278848+00:00",
              "published_date": null,
              "source_hash": "96bb412e8b69b03dd5fe7275472b1db9"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "GH Research PLC regulatory challenges 5-MeO-DMT",
              "rationale": "Investigate legal and regulatory hurdles related to the controlled substance status of 5-MeO-DMT",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "GH Research PLC public perception psychedelic therapies",
              "rationale": "Explore public and investor skepticism regarding the safety and efficacy of psychedelic-based treatments",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "GH Research PLC clinical trial risks delays",
              "rationale": "Assess potential risks and delays in ongoing and future clinical trials for GH001 and other pipeline candidates",
              "priority": 1
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T11:14:45.763859",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}